Moderna (NASDAQ:MRNA) Given New $200.00 Price Target at Morgan Stanley

Moderna (NASDAQ:MRNA – Get Free Report) had its price objective increased by research analysts at Morgan Stanley from $95.00 to $200.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley‘s price objective would indicate a potential downside of 7.09% from the stock’s current price.

Several other brokerages also recently issued reports on MRNA. Jefferies Financial Group reissued a “hold” rating and set a $150.00 price target (up from $60.00) on shares of Moderna in a report on Wednesday, August 19th. Berenberg Bank upped their price objective on shares of Moderna from $45.00 to $100.00 and gave the stock a “hold” rating in a research note on Friday, September 11th. Citigroup reaffirmed a “sell” rating on shares of Moderna in a research note on Friday, October 23rd. Brookline Capital Markets reaffirmed a “buy” rating on shares of Moderna in a report on Wednesday, August 19th. Finally, TD Cowen reiterated a “buy” rating on shares of Moderna in a research note on Wednesday, October 21st. Six research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $119.00.

Check Out Our Latest Report on Moderna

Moderna Price Performance

Moderna stock opened at $215.27 on Tuesday. The company has a current ratio of 3.62, a quick ratio of 3.47 and a debt-to-equity ratio of 0.52. The stock has a fifty day moving average price of $203.06 and a two-hundred day moving average price of $97.26. Moderna has a 52-week low of $22.28 and a 52-week high of $280.80.

Moderna (NASDAQ:MRNA – Get Free Report) last issued its earnings results on Friday, November 6th. The company reported $0.38 EPS for the quarter, beating the consensus estimate of ($1.10) by $1.48. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The company had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $890.25 million. During the same quarter in the previous year, the company earned ($0.51) EPS. The firm’s revenue for the quarter was up 29.2% compared to the same quarter last year. On average, equities research analysts anticipate that Moderna will post -5.14 earnings per share for the current year.

Insider Transactions at Moderna

In other news, insider Shannon Klinger sold 3,471 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the sale, the insider owned 74,129 shares in the company, valued at approximately $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jamey Mock sold 34,836 shares of the firm’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the sale, the chief financial officer owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 197,251 shares of company stock worth $33,875,904. Insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Moderna

Hedge funds have recently added to or reduced their stakes in the stock. Ethic Inc. raised its stake in shares of Moderna by 23.6% in the third quarter. Ethic Inc. now owns 19,394 shares of the company’s stock worth $3,735,000 after acquiring an additional 3,700 shares during the last quarter. Merck & Co. Inc. bought a new stake in shares of Moderna during the second quarter valued at approximately $161,642,545. Bank of New York Mellon Corp bought a new stake in shares of Moderna during the second quarter valued at approximately $119,168,000. Contravisory Investment Management Inc. grew its stake in shares of Moderna by 1,387.6% during the second quarter. Contravisory Investment Management Inc. now owns 24,218 shares of the company’s stock valued at $1,696,000 after purchasing an additional 22,590 shares during the last quarter. Finally, TD Waterhouse Canada Inc. increased its holdings in shares of Moderna by 2,042.6% in the third quarter. TD Waterhouse Canada Inc. now owns 72,591 shares of the company’s stock valued at $13,722,000 after purchasing an additional 69,203 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

(Get Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Further Reading

Analyst Recommendations for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.